Currently, an RCT (ClinicalTrials.gov Identifier: NCT05327127) is being undertaken to assess the effects of pemafibrate and/or an SGLT2 inhibitor on patients with NAFLD. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.